Skip to main content

Table 2 Medication use

From: Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation

 

DM (n = 149)

Non-DM (n = 188)

p value

At the time of PCI

 Aspirin, n (%)

139 (93)

173 (92)

0.41

 Clopidogrel, n (%)

73 (49)

112 (60)

0.061

 Prasugrel, n (%)

52 (35)

53 (28)

0.20

 Ticlopidine, n (%)

7 (5)

8 (4)

1.0

  Statin, n (%)

80 (54)

92 (49)

0.22

 Insulin, n (%)

24 (16)

0 (0)

N/A

 Biguanide, n (%)

38 (26)

0 (0)

N/A

 DPP-4 inhibitor, n (%)

59 (40)

0 (0)

N/A

 SGLT-2 inhibitor, n (%)

4 (3)

0 (0)

N/A

 Thiazolidine, n (%)

18 (12)

0 (0)

N/A

 Sulfonylurea, n (%)

39 (26)

0 (0)

N/A

 Glinide, n (%)

6 (4)

0 (0)

N/A

 α-glucosidase inhibitor, n (%)

26 (17)

0 (0)

N/A

At the time of CAS evaluation

 Aspirin, n (%)

149 (100)

186 (99)

0.31

 Clopidogrel, n (%)

79 (53)

104 (55)

0.74

 Prasugrel, n (%)

63 (42)

64 (34)

0.14

 Ticlopidine, n (%)

6 (4)

8 (4)

1.0

 Statin, n (%)

102 (69)

142 (76)

0.094

 Insulin, n (%)

25 (17)

0 (0)

N/A

 Biguanide, n (%)

43 (29)

0 (0)

N/A

 DPP-4 inhibitor, n (%)

62 (42)

0 (0)

N/A

 SGLT-2 inhibitor, n (%)

5 (3)

0 (0)

N/A

 Thiazolidine, n (%)

18 (12)

0 (0)

N/A

 Sulfonylurea, n (%)

40 (27)

0 (0)

N/A

 Glinide, n (%)

10 (7)

0 (0)

N/A

 α-glucosidase inhibitor, n (%)

31 (21)

0 (0)

N/A

  1. Data are presented as number (%)
  2. CAS  coronary angioscopy, DM  diabetes mellitus, DPP-4 dipeptidyl peptidase-4, N/A  not available, SGLT-2  sodium glucose cotransporter-2